Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Roche patents novel dual 5-HT2A/D3 receptor modulators

March 10, 2009

Orion withdraws E.U. application to extend indication of Stalevo

March 9, 2009

Entorhinal BDNF gene delivery neuroprotective in Alzheimer's disease models

March 9, 2009

Preliminary phase II study results for SEP-225441 do not meet endpoint in GAD

March 9, 2009

Yamada Apiculture Center presents novel antidepressant compound

March 9, 2009

Merck & Co. discloses novel orexin receptor antagonists for insomnia

March 6, 2009

Acura's NDA for Acurox accepted by FDA for filing with priority review

March 5, 2009

Immunomodulation via Toll-like receptors may be beneficial in Alzheimer's disease

March 5, 2009

FDA approves Copaxone for patients with a first clinical event of MS

March 5, 2009

Sonexa Therapeutics evaluates efficacy and safety of ST-101 in Alzheimer's disease

March 5, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...